PHXM — Phaxiam Therapeutics SA Balance Sheet
0.000.00%
- €0.61m
- €12.08m
- €1.33m
Annual balance sheet for Phaxiam Therapeutics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 73.2 | 44.5 | 33.7 | 38.8 | 10.5 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5.82 | 4.33 | 5.09 | 3.04 | 5.08 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 81.6 | 49.6 | 40 | 42.6 | 16.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 35.6 | 29.1 | 25.8 | 2.98 | 3.9 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 119 | 80.4 | 66.8 | 45.8 | 51.3 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 19.9 | 29.3 | 20 | 11.7 | 15.3 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 33 | 53.9 | 43.9 | 22.3 | 25.7 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 85.6 | 26.5 | 22.8 | 23.5 | 25.6 |
| Total Liabilities & Shareholders' Equity | 119 | 80.4 | 66.8 | 45.8 | 51.3 |
| Total Common Shares Outstanding |